Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$133.09 USD
-0.37 (-0.28%)
Updated Aug 14, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 301 - 320 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT
Provider: Stock Traders Daily
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Peer-Related Distraction Weighing on the Stock; Focus on Micro-Dystrophin Positive Fibers as an Indicator of Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Firming up 2020 Estimates Post Casimersen Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Functional Gains With SRP-9001 Bode Well for the Registration Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NSAA and CK Are Not Chance Events; Bodes Well for Ongoing and Planned Registration Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Passion Is Empowering, the Foundations Are Solid, and the Sky Might Be the Limit, but Let''s Be Deliberate
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Collaborator Provides an Early Look at Genome Editing for DMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting b-SG Expression in the Low Teens From Cohort-1
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Peer Data Underwhelms; If This Trajectory Holds, Sarepta?s 12 to 18-Month Lead Is Insurmountable
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Micro Dystrophin Gene Therapy Post Management Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D